Glycosaminoglycan

Revision as of 19:45, 15 April 2015 by Aparna Vuppala (talk | contribs)
Jump to navigation Jump to search


WikiDoc Resources for Glycosaminoglycan

Articles

Most recent articles on Glycosaminoglycan

Most cited articles on Glycosaminoglycan

Review articles on Glycosaminoglycan

Articles on Glycosaminoglycan in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Glycosaminoglycan

Images of Glycosaminoglycan

Photos of Glycosaminoglycan

Podcasts & MP3s on Glycosaminoglycan

Videos on Glycosaminoglycan

Evidence Based Medicine

Cochrane Collaboration on Glycosaminoglycan

Bandolier on Glycosaminoglycan

TRIP on Glycosaminoglycan

Clinical Trials

Ongoing Trials on Glycosaminoglycan at Clinical Trials.gov

Trial results on Glycosaminoglycan

Clinical Trials on Glycosaminoglycan at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Glycosaminoglycan

NICE Guidance on Glycosaminoglycan

NHS PRODIGY Guidance

FDA on Glycosaminoglycan

CDC on Glycosaminoglycan

Books

Books on Glycosaminoglycan

News

Glycosaminoglycan in the news

Be alerted to news on Glycosaminoglycan

News trends on Glycosaminoglycan

Commentary

Blogs on Glycosaminoglycan

Definitions

Definitions of Glycosaminoglycan

Patient Resources / Community

Patient resources on Glycosaminoglycan

Discussion groups on Glycosaminoglycan

Patient Handouts on Glycosaminoglycan

Directions to Hospitals Treating Glycosaminoglycan

Risk calculators and risk factors for Glycosaminoglycan

Healthcare Provider Resources

Symptoms of Glycosaminoglycan

Causes & Risk Factors for Glycosaminoglycan

Diagnostic studies for Glycosaminoglycan

Treatment of Glycosaminoglycan

Continuing Medical Education (CME)

CME Programs on Glycosaminoglycan

International

Glycosaminoglycan en Espanol

Glycosaminoglycan en Francais

Business

Glycosaminoglycan in the Marketplace

Patents on Glycosaminoglycan

Experimental / Informatics

List of terms related to Glycosaminoglycan

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Chondroitin sulfate
Hyaluronan (-4GlcUAβ1-3GlcNAcβ1-)n

Glycosaminoglycans (GAGs) or mucopolysaccharides are long unbranched polysaccharides consisting of a repeating disaccharide unit.

Production

Protein cores made in the rough endoplasmic reticulum are posttranslationally modified by glycosyltransferases in the Golgi apparatus, where GAG disaccharides are added to protein cores; the exception is hyaluronan, which is uniquely synthesized without a protein core and is "spun out" by enzymes at cell surfaces directly into the extracellular space.

Structure

This unit consists of an N-acetyl-hexosamine and a hexose or hexuronic acid, either or both of which may be sulfated.

The combination of the sulfate group and the carboxylate groups of the uronic acid residues gives them a very high density of negative charge.

Function

This family of carbohydrates is essential or important for the life of vertebrates and an assortment of lower animals.

GAGs form an important component of connective tissues. GAG chains may be covalently linked to a protein to form proteoglycans.

Some examples of glycoaminoglycan uses in nature include heparin as an anticoagulant, hyaluronate as a component in the synovial fluid lubricant in body joints, and chondroitins which can be found in connective tissues, cartilage and tendons.

Classification

Members of the glycosaminoglycan family vary in the type of hexosamine, hexose or hexuronic acid unit they contain (e.g. glucuronic acid, iduronic acid, galactose, galactosamine, glucosamine).

They also vary in the geometry of the glycosidic linkage.

Examples of GAGs include:

Name Hexuronic acid / Hexose Hexosamine Linkage geometry between predominant monomeric units Unique features
Chondroitin sulphate GlcUA or GlcUA(2S) GalNAc or GalNAc(4S) or GalNAc(6S) or GalNAc(4S,6S) -4GlcUAβ1-3GalNAcβ1- Most prevalent GAG
Dermatan sulphate GlcUA or IdoUA or IdoUA(2S) GalNAc or GalNAc(4S) or GalNAc(6S) or GalNAc(4S,6S) -4IdoUAβ1-3GalNAcβ1- Distinguished from chondroitin sulfate by the presence of iduronic acid, although some hexuronic acid monosaccharides may be glucuronic acid.[1]
Keratan sulphate Gal or Gal(6S) GlcNAc or GlcNAc(6S) -3Gal(6S)β1-4GlcNAc(6S)β1- Keratan sulfate type II may be fucosylated.[2]
Heparin GlcUA or IdoUA(2S) GlcNAc or GlcNS or GlcNAc(6S) or GlcNS(6S) -4IdoUA(2S)α1-4GlcNS(6S)α1- Highest negative charge density of any known biological molecule
Heparan sulfate GlcUA or IdoUA or IdoUA(2S) GlcNAc or GlcNS or GlcNAc(6S) or GlcNS(6S) -4GlcUAβ1-4GlcNAcα1- Highly similar in structure to heparin, however heparan sulfates disaccharide units are organised into distinct sulfated and non-sulfated domains.[3]
Hyaluronan GlcUA GlcNAc -4GlcUAβ1-3GlcNAcβ1- The only GAG that is exclusively non-sulfated

Abbreviations

  • GlcUA = β-D-glucuronic acid
  • GlcUA(2S) = 2-O-sulfo-β-D-glucuronic acid
  • IdoUA = α-L-iduronic acid
  • IdoUA(2S) = 2-O-sulfo-α-L-iduronic acid
  • Gal = β-D-galactose
  • Gal(6S) = 6-O-sulfo-β-D-galactose
  • GalNAc = β-D-N-acetylgalactosamine
  • GalNAc(4S) = β-D-N-acetylgalactosamine-4-O-sulfate
  • GalNAc(6S) = β-D-N-acetylgalactosamine-6-O-sulfate
  • GalNAc(4S,6S) = β-D-N-acetylgalactosamine-4-O, 6-O-sulfate
  • GlcNAc = α-D-N-acetylglucosamine
  • GlcNS = α-D-N-sulfoglucosamine
  • GlcNS(6S) = α-D-N-sulfoglucosamine-6-O-sulfate

References

  1. Trowbridge JM, Gallo RL. (2002). "Dermatan sulfate: new functions from an old glycosaminoglycan". Glycobiology. 12 (9): 117R–125R. PMID 12213784.
  2. Funderburgh JL. (2000). "Keratan sulfate: structure, biosynthesis, and function". Glycobiology. 10 (10): 951–958. PMID 11030741.
  3. Gallagher, J.T., Lyon, M. (2000). "Molecular structure of Heparan Sulfate and interactions with growth factors and morphogens". In Iozzo, M, V. Proteoglycans: structure, biology and molecular interactions. Marcel Dekker Inc. New York, New York. pp. 27–59.

See also

External links

Template:Glycosaminoglycans